YOLFTbeta
19

HLB Pep Co., Ltd.

196300 · KQ · Basic Materials / Chemicals

3,345.00KRW-55.00 (-1.62%)

Price History

Full chart

Market Stats

Previous Close3,400.00
Open3,420.00
Day Range3,305.00 – 3,450.00
52-Week Range3,510.00 – 9,530.00
Volume5.54K
Market Cap42.99B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.23
50-Day Avg4,339.50
200-Day Avg6,136.55

About

HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes; AGM-217 indicated for the treatment of Type 2 diabetes and obesity; and AGM-260 indicated for the treatment of Ulcerative colitis. The company was formerly known as Anygen Co., Ltd. and changed its name to HLB Pep Co., Ltd. in April 2025. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.

Company Details

  • SectorBasic Materials
  • IndustryChemicals
  • CEOMr. Jae Il Kim
  • HeadquartersGwangju Technopark, Gwangju-si, South Korea, 61008, Korea
  • Websitehttps://hlbpep.co.kr

Leadership

  • Mr. Jae Il KimCEO & Director
  • Kyoung Jae ShimCEO & Director
  • Ji-Yong ParkR&D Director & Director · b. 1968
  • Tae Il LeeDirector of Audit & Director
  • You Deok KimExecutive Director
  • YuDeok KimMD & Executive Director
  • GukSang HwangManaging Director
  • KyungNam KimDirector of Audit & Director
  • Yeong Su JeonDirector of Audit & Director

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue8.66B5.61B6.23B4.96B
Growth (%)--35.23%+11.02%-20.34%
Cost of Revenue8.14B8.05B7.15B6.71B
Gross Profit524.57M-2.44B-918.65M-1.74B
Gross Margin6.06%-43.52%-14.75%-35.15%
Operating Expense4.85B4.27B4.52B5.58B
Operating Income-4.32B-6.72B-5.44B-7.32B
Operating Margin-49.93%-119.71%-87.33%-147.53%
EBITDA-2.45B-5.39B-3.91B4.59B
EBITDA Margin-28.30%-96.03%-62.81%92.56%
Net Income-6.20B-9.08B-6.79B-642.47M
Net Income Margin-71.63%-161.82%-109.06%-12.95%
R&D2.10B1.49B1.28B3.48B
R&D as % of Total Revenue24.23%26.62%20.55%70.16%
Interest Expense809.80M823.04M388.54M2.90B
Interest Expense % of Total Revenue9.35%14.67%6.24%58.44%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets25.89B21.00B16.52B53.81B
Total Liabilities12.49B10.48B11.14B28.07B
Total Equity13.40B10.52B5.38B25.73B
Cash480.05M1.01B201.24M1.51B
Net Debt7.66B5.85B7.43B15.15B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.55B-3.38B-2.10B-5.57B
Capital Expenditure1.93B654.73M476.35M5.43B
Free Cash Flow-4.47B-4.04B-2.58B-11.01B
FCF to OCF175.57%119.36%122.64%197.45%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------
EPS Actual13.0088.7038.39-49.00-57.03-310.70-232.80-823.56-309.91-317.58-227.60-469.55-218.92-106.42-124.17-41.27-158.93-340.06-121.18267.20-205.51-15.25-268.64-618.88-192.82-442.16-154.00-784.56-203.85-249.00-246.00-463.53-244.00-87.68-220.75279.56-322.86-78.55
Surprise--------------------------------------
Timing--------------------------------------

Key Statistics & Ratios

Market Cap42.99B
Enterprise Value32.89B
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.76
Price / Book1.74
Revenue (TTM)5.54B
Gross Profit (TTM)-1.54B
EBITDA-5.42B
Profit Margin-57.54%
Operating Margin-109.80%
Return on Equity-13.38%
Return on Assets-9.15%
Shares Outstanding9.38M
Shares Float5.14M
Beta0.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Feb 28, 20241.3:1
  • Jan 3, 20241.3:1